Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2002 Mar;282(3):G424-31.
doi: 10.1152/ajpgi.2002.282.3.G424.

Effect of GLP-1 on Gastric Volume, Emptying, Maximum Volume Ingested, and Postprandial Symptoms in Humans

Affiliations
Free article
Clinical Trial

Effect of GLP-1 on Gastric Volume, Emptying, Maximum Volume Ingested, and Postprandial Symptoms in Humans

Silvia Delgado-Aros et al. Am J Physiol Gastrointest Liver Physiol. .
Free article

Abstract

Glucagon-like peptide-1 (GLP-1) relaxes the stomach during fasting but decreases hunger and food consumption and retards gastric emptying. The interrelationships between volume, emptying, and postprandial symptoms in response to GLP-1 are unclear. We performed, in healthy human volunteers, a placebo-controlled study of the effects of intravenous GLP-1 on gastric volume using (99m)Tc-single photon emission computed tomography imaging, gastric emptying of a nutrient liquid meal (Ensure) using scintigraphy, maximum tolerated volume (MTV) of Ensure, and postprandial symptoms 30 min after MTV. The role of vagal cholinergic function in the effects of GLP-1 was assessed by human pancreatic polypeptide (HPP) response to the Ensure meal. GLP-1 increased fasting and postprandial gastric volumes and retarded gastric emptying; MTV and postprandial symptoms were not different compared with controls. Effects on postprandial gastric function were associated with reduced postprandial HPP levels. GLP-1 does not induce postprandial symptoms despite significant inhibition of gastric emptying and vagal function; this may be partly explained by the increase in postprandial gastric volume.

Similar articles

See all similar articles

Cited by 57 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback